[1]
|
Sand KM, Bern M, Nilsen J, et al. Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics[J]. Front Immunol, 2014, 5: 682. |
[2]
|
Liu Z, Chen X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy[J]. Chem Soc Rev, 2016, 45: 1432-1456. doi: 10.1039/C5CS00158G |
[3]
|
Evans HM, Schulemann W. The Action of Vital Stains Belonging to the Benzidine Group[J]. Science, 1914, 39: 443-454. doi: 10.1126/science.39.1004.443 |
[4]
|
Freedman FB, Johnson JA. Equilibrium and kinetic properties of the Evans blue-albumin system[J]. Am J Physiol, 1969, 216: 675-681. doi: 10.1152/ajplegacy.1969.216.3.675 |
[5]
|
Niu G, Lang L, Kiesewetter DO, et al. In Vivo Labeling of Serum Albumin for PET[J]. J Nucl Med, 2014, 55: 1150-1156. doi: 10.2967/jnumed.114.139642 |
[6]
|
Wang Y, Lang L, Huang P, et al. In vivo albumin labeling and lymphatic imaging[J]. Proc Natl Acad Sci U S A, 2015, 112: 208-213. doi: 10.1073/pnas.1414821112 |
[7]
|
Zhang J, Lang L, Zhu Z, et al. Clinical Translation of an Albumin-Binding PET Radiotracer 68Ga-NEB[J]. J Nucl Med, 2015, 56: 1609-1614. doi: 10.2967/jnumed.115.159640 |
[8]
|
Zang J, Liu Q, Sui H, et al. Combined (68)Ga-NOTA-Evans Blue Lymphoscintigraphy and (68)Ga-NOTA-RM26 PET/CT Evaluation of Sentinel Lymph Node Metastasis in Breast Cancer Patients[J]. Bioconjug Chem, 2020, 31: 396-403. doi: 10.1021/acs.bioconjchem.9b00789 |
[9]
|
Long X, Zhang J, Zhang D, et al. Microsurgery guided by sequential preoperative lymphography using (68)Ga-NEB PET and MRI in patients with lower-limb lymphedema[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 1501-1510. doi: 10.1007/s00259-017-3676-6 |
[10]
|
Zhang W, Wu P, Li F, et al. Potential Applications of Using 68Ga-Evans Blue PET/CT in the Evaluation of Lymphatic Disorder: Preliminary Observations[J]. Clin Nucl Med, 2016, 41: 302-308. doi: 10.1097/RLU.0000000000001171 |
[11]
|
Hou G, Jiang Y, Xu W, et al. (68)Ga-NOTA-Evans Blue PET/CT findings in lymphangioleiomyomatosis compared with (99m)TC-ASC lymphoscintigraphy: a prospective study[J]. Orphanet J Rare Dis, 2021, 16: 279. doi: 10.1186/s13023-021-01895-1 |
[12]
|
Hou G, Hou B, Jiang Y, et al. 68Ga-NOTA-Evans Blue TOF PET/MR Lymphoscintigraphy Evaluation of the Severity of Lower Limb Lymphedema[J]. Clin Nucl Med, 2019, 44: 439-445. doi: 10.1097/RLU.0000000000002584 |
[13]
|
Chen H, Tong X, Lang L, et al. Quantification of Tumor Vascular Permeability and Blood Volume by Positron Emission Tomography[J]. Theranostics, 2017, 7: 2363-2376. doi: 10.7150/thno.19898 |
[14]
|
Bombardieri E, Maccauro M, De Deckere E, et al. Nuclear medicine imaging of neuroendocrine tumours[J]. Ann Oncol, 2001, 12 Suppl 2: S51-S61. |
[15]
|
Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors[J]. J Nucl Med, 2018, 59: 66-74. doi: 10.2967/jnumed.117.202275 |
[16]
|
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. doi: 10.1056/NEJMoa1607427 |
[17]
|
Tian R, Jacobson O, Niu G, et al. Evans Blue Attachment Enhances Somatostatin Receptor Subtype-2 Imaging and Radiotherapy[J]. Theranostics, 2018, 8: 735-745. doi: 10.7150/thno.23491 |
[18]
|
Bandara N, Jacobson O, Mpoy C, et al. Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent[J]. Bioconjug Chem, 2018, 29: 2448-2454. doi: 10.1021/acs.bioconjchem.8b00341 |
[19]
|
Zhang J, Wang H, Jacobson O, et al. Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue (177)Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors[J]. J Nucl Med, 2018, 59: 1699-1705. doi: 10.2967/jnumed.118.209841 |
[20]
|
Wang H, Cheng Y, Zhang J, et al. Response to Single Low-dose (177)Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study[J]. Theranostics, 2018, 8: 3308-3316. doi: 10.7150/thno.25919 |
[21]
|
Liu Q, Cheng Y, Zang J, et al. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog (177)Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors[J]. Eur J Nucl Med Mol Imaging, 2020, 47: 947-957. doi: 10.1007/s00259-019-04530-1 |
[22]
|
Liu Q, Zang J, Sui H, et al. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of (177)Lu-DOTA-EB-TATE[J]. J Nucl Med, 2021, 62: 386-392. doi: 10.2967/jnumed.120.248658 |
[23]
|
Bergsma H, Konijnenberg MW, Kam BL, et al. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course[J]. Eur J Nucl Med Mol Imaging, 2016, 43: 453-463. doi: 10.1007/s00259-015-3193-4 |
[24]
|
Sabet A, Dautzenberg K, Haslerud T, et al. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine[J]. Eur J Nucl Med Mol Imaging, 2015, 42: 1238-1246. doi: 10.1007/s00259-015-3041-6 |
[25]
|
Sabet A, Haslerud T, Pape UF, et al. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 205-210. doi: 10.1007/s00259-013-2547-z |
[26]
|
Delpassand ES, Samarghandi A, Zamanian S, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience[J]. Pancreas, 2014, 43: 518-525. doi: 10.1097/MPA.0000000000000113 |
[27]
|
Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors[J]. Eur J Nucl Med Mol Imaging, 2015, 42: 5-19. doi: 10.1007/s00259-014-2893-5 |
[28]
|
Paganelli G, Sansovini M, Ambrosetti A, et al. 177Lu-DOTA-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase Ⅱ study[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 1845-1851. doi: 10.1007/s00259-014-2735-5 |
[29]
|
Sabet A, Ezziddin K, Pape UF, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate[J]. J Nucl Med, 2013, 54: 1857-1861. doi: 10.2967/jnumed.112.119347 |
[30]
|
Jonathan S, Edward W, Beth C, et al. NETTER-1 Phase Ⅲ in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results[J]. J Nucl Med, 2016, 57: 629. |
[31]
|
Brieau B, Hentic O, Lebtahi R, et al. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy[J]. Endocr Relat Cancer, 2016, 23: L17-L23. doi: 10.1530/ERC-15-0543 |
[32]
|
Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues[J]. Clin Cancer Res, 1997, 3: 81-85. |
[33]
|
Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression[J]. Hum Pathol, 2007, 38: 696-701. doi: 10.1016/j.humpath.2006.11.012 |
[34]
|
Wang W, Tavora F, Sharma R, et al. PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma[J]. Urol Oncol, 2009, 27: 525-528. doi: 10.1016/j.urolonc.2008.04.007 |
[35]
|
Marchal C, Redondo M, Padilla M, et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia[J]. Histol Histopathol, 2004, 19: 715-718. |
[36]
|
Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies[J]. J Nucl Med, 2015, 56: 1169-1176. doi: 10.2967/jnumed.115.158550 |
[37]
|
Benesova M, Schafer M, Bauder-Wust U, et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer[J]. J Nucl Med, 2015, 56: 914-920. doi: 10.2967/jnumed.114.147413 |
[38]
|
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer[J]. N Engl J Med, 2021, 385: 1091-1103. doi: 10.1056/NEJMoa2107322 |
[39]
|
Wang Z, Jacobson O, Tian R, et al. Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent (90)Y-DOTA-EB-MCG[J]. Bioconjug Chem, 2018, 29: 2309-2315. doi: 10.1021/acs.bioconjchem.8b00292 |
[40]
|
Wang Z, Tian R, Niu G, et al. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors[J]. Bioconjug Chem, 2018, 29: 3213-3221. doi: 10.1021/acs.bioconjchem.8b00556 |
[41]
|
Zang J, Fan X, Wang H, et al. First-in-human study of (177)Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2019, 46: 148-158. doi: 10.1007/s00259-018-4096-y |
[42]
|
Zang J, Liu Q, Sui H, et al. (177)Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer[J]. J Nucl Med, 2020, 61: 1772-1778. doi: 10.2967/jnumed.120.242263 |
[43]
|
Hofman MS, Violet J, Hicks RJ, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19: 825-833. doi: 10.1016/S1470-2045(18)30198-0 |